- Home
- IMCR
as of 12-09-2025 3:59pm EST
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
| Founded: | 2008 | Country: | United Kingdom |
| Employees: | N/A | City: | OXFORDSHIRE |
| Market Cap: | 1.7B | IPO Year: | 2021 |
| Target Price: | $67.00 | AVG Volume (30 days): | 292.7K |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.58 | EPS Growth: | N/A |
| 52 Week Low/High: | $23.15 - $40.72 | Next Earning Date: | 11-06-2025 |
| Revenue: | $379,590,000 | Revenue Growth: | 28.11% |
| Revenue Growth (this year): | 32.31% | Revenue Growth (next year): | 10.50% |
AI-Powered IMCR Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Immunocore Holdings plc (IMCR)
HEAD OF R&D
Avg Cost/Share
$40.14
Shares
572
Total Value
$22,960.08
Owned After
0
SEC Form 4
HEAD OF R&D
Avg Cost/Share
$40.26
Shares
31,341
Total Value
$1,261,788.66
Owned After
0
SEC Form 4
HEAD OF R&D
Avg Cost/Share
$40.09
Shares
5,521
Total Value
$221,336.89
Owned After
0
SEC Form 4
HEAD OF R&D
Avg Cost/Share
$40.12
Shares
69,404
Total Value
$2,784,488.48
Owned After
0
SEC Form 4
HEAD OF R&D
Avg Cost/Share
$40.03
Shares
18,020
Total Value
$721,340.60
Owned After
0
SEC Form 4
HEAD OF R&D
Avg Cost/Share
$40.00
Shares
100
Total Value
$4,000.00
Owned After
0
SEC Form 4
HEAD OF R&D
Avg Cost/Share
$35.23
Shares
61,849
Total Value
$2,178,940.27
Owned After
0
SEC Form 4
HEAD OF R&D
Avg Cost/Share
$35.01
Shares
200
Total Value
$7,002.00
Owned After
0
SEC Form 4
HEAD OF R&D
Avg Cost/Share
$35.97
Shares
22,532
Total Value
$803,699.16
Owned After
0
HEAD OF R&D
Avg Cost/Share
$36.28
Shares
19,081
Total Value
$692,258.68
Owned After
0
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Berman David M | IMCR | HEAD OF R&D | Dec 5, 2025 | Sell | $40.14 | 572 | $22,960.08 | 0 | |
| Berman David M | IMCR | HEAD OF R&D | Dec 4, 2025 | Sell | $40.26 | 31,341 | $1,261,788.66 | 0 | |
| Berman David M | IMCR | HEAD OF R&D | Nov 28, 2025 | Sell | $40.09 | 5,521 | $221,336.89 | 0 | |
| Berman David M | IMCR | HEAD OF R&D | Nov 26, 2025 | Sell | $40.12 | 69,404 | $2,784,488.48 | 0 | |
| Berman David M | IMCR | HEAD OF R&D | Nov 25, 2025 | Sell | $40.03 | 18,020 | $721,340.60 | 0 | |
| Berman David M | IMCR | HEAD OF R&D | Nov 24, 2025 | Sell | $40.00 | 100 | $4,000.00 | 0 | |
| Berman David M | IMCR | HEAD OF R&D | Sep 30, 2025 | Sell | $35.23 | 61,849 | $2,178,940.27 | 0 | |
| Berman David M | IMCR | HEAD OF R&D | Sep 15, 2025 | Sell | $35.01 | 200 | $7,002.00 | 0 | |
| Berman David M | IMCR | HEAD OF R&D | Sep 12, 2025 | Sell | $35.97 | 22,532 | $803,699.16 | 0 | |
| Berman David M | IMCR | HEAD OF R&D | Sep 11, 2025 | Sell | $36.28 | 19,081 | $692,258.68 | 0 |
Compare IMCR vs Leading Stocks
See how IMCR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "IMCR Immunocore Holdings plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.